Protoplanetary disc rings planet formation research may need rethinking: a Heidelberg University parameter study shows one migrating planet in a calm, low-viscosity disc can produce multiple dust ring ...

Declining ARPU and limited scale mean it cannot alone justify SpaceX’s current valuation without extraordinary AI or space ...

Fog machines are an underrated and, frankly, underutilized device when it comes to Halloween hijinks. An intelligently placed ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Anand Gopal had never considered working with a stylist. "I always thought personal stylists were for ...

As more and more data centers are proposed throughout the region and the state, the issues critics bring to the table are becoming fairly familiar — the amount of water used to cool the servers, air ...

Has Elon Musk given up on Tesla’s Master Plans, on the electrified economy, on solar power as we know it? From the SpaceX IPO filing released this week, it sure seems like it. A recap for those not ...

Driving an RV lets you bring the comforts of home along on your road trip, but having a portable generator is essential. It powers your electric appliances and charges electronics, like your phone and ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...